Skip to main content

Table 1 Dose levels

From: A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Dose level (DL)

Durvalumab (IV)

Olaparib tablet (oral)

Cediranib (oral)

DL − 1

1500 mg every 4 weeks

200 mg twice daily

15 mg once daily

(5 days on/2 days off)

DL 1 (starting dose)

1500 mg every 4 weeks

300 mg twice daily

15 mg once daily

(5 days on/2 days off)

DL 2

1500 mg every 4 weeks

300 mg twice daily

20 mg once daily

(5 days on/2 days off)